Skip to contentP
Panacea Life Sciences Holdings, Inc.
P
PLSHPanacea Life Sciences Holdings, Inc. Q1 2022 · 10-Q
Revenue$466.47K$466.47K−8.9% vs Q1 2021 Net Income-$2.78M-$2.78MN/M vs Q1 2021 EPS Diluted-$0.19-$0.19N/M vs Q1 2021 Gross Profit$100,383−44.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Panacea Life Sciences Holdings, Inc. · CIK 1552189 · Engraved from SEC EDGAR
Operating Cash Flow-$436,043N/M Free Cash Flowderived-$445,768N/M Margins · derivedGross margin21.5%−14.1 pt vs Q1 2021
Operating margin-353.3%−140.1 pt vs Q1 2021
Net margin-596.4%−668.8 pt vs Q1 2021
ended Mar 31, 2022 · filed May 13, 2022 · 43 d after period end